Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.

Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, Kohler BA, Jemal A.

Cancer. 2018 May 22. doi: 10.1002/cncr.31551. [Epub ahead of print]

PMID:
29786848
2.

Differences in Breast Cancer Survival by Molecular Subtypes in the United States.

Howlader N, Cronin KA, Kurian AW, Andridge R.

Cancer Epidemiol Biomarkers Prev. 2018 Mar 28. doi: 10.1158/1055-9965.EPI-17-0627. [Epub ahead of print]

PMID:
29593010
3.

Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.

Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S.

NPJ Breast Cancer. 2016 Jun 8;2:16017. doi: 10.1038/npjbcancer.2016.17. eCollection 2016.

4.

Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.

Howlader N, Mariotto AB, Besson C, Suneja G, Robien K, Younes N, Engels EA.

Cancer. 2017 Sep 1;123(17):3326-3334. doi: 10.1002/cncr.30739. Epub 2017 May 2.

PMID:
28464214
5.

Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992-2013.

Noone AM, Cronin KA, Altekruse SF, Howlader N, Lewis DR, Petkov VI, Penberthy L.

Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):632-641. doi: 10.1158/1055-9965.EPI-16-0520. Epub 2016 Dec 12.

6.

Imputing estrogen receptor (ER) status in a population-based cancer registry: a sensitivity analysis.

Andridge R, Noone AM, Howlader N.

Stat Med. 2017 Mar 15;36(6):1014-1028. doi: 10.1002/sim.7193. Epub 2016 Dec 5.

PMID:
27921315
7.

Contributions of HIV to Non-Hodgkin Lymphoma Mortality Trends in the United States.

Howlader N, Shiels MS, Mariotto AB, Engels EA.

Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1289-96. doi: 10.1158/1055-9965.EPI-16-0273. Epub 2016 Jul 14.

8.

Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends.

Howlader N, Morton LM, Feuer EJ, Besson C, Engels EA.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):174-9. doi: 10.1158/1055-9965.EPI-15-0921. Epub 2015 Oct 15.

9.

Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.

Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, Boscoe FP, Cronin KA, Lake A, Noone AM, Henley SJ, Eheman CR, Anderson RN, Penberthy L.

J Natl Cancer Inst. 2015 Mar 30;107(6):djv048. doi: 10.1093/jnci/djv048. Print 2015 Jun. Erratum in: J Natl Cancer Inst. 2015 May;107(5). pii: djv121. doi: 10.1093/jnci/djv121. J Natl Cancer Inst. 2015 Jul;107(7). pii: djv177. doi: 10.1093/jnci/djv177.

10.

Providing clinicians and patients with actual prognosis: cancer in the context of competing causes of death.

Howlader N, Mariotto AB, Woloshin S, Schwartz LM.

J Natl Cancer Inst Monogr. 2014 Nov;2014(49):255-64. doi: 10.1093/jncimonographs/lgu022.

11.

Cancer survival: an overview of measures, uses, and interpretation.

Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, Woloshin S, Schwartz LM.

J Natl Cancer Inst Monogr. 2014 Nov;2014(49):145-86. doi: 10.1093/jncimonographs/lgu024. Erratum in: J Natl Cancer Inst Monogr. 2015 May;2015(51):97.

12.

Overview of breast cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010.

Howlader N, Chen VW, Ries LA, Loch MM, Lee R, DeSantis C, Lin CC, Ruhl J, Cronin KA.

Cancer. 2014 Dec 1;120 Suppl 23:3771-80. doi: 10.1002/cncr.29059.

13.

US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.

Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA.

J Natl Cancer Inst. 2014 Apr 28;106(5). pii: dju055. doi: 10.1093/jnci/dju055.

14.

Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer.

Howlader N, Noone AM, Yu M, Cronin KA.

Am J Epidemiol. 2012 Aug 15;176(4):347-56. doi: 10.1093/aje/kwr512. Epub 2012 Jul 25.

15.

Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.

Potosky AL, Malin JL, Kim B, Chrischilles EA, Makgoeng SB, Howlader N, Weeks JC.

J Natl Cancer Inst. 2011 Jun 22;103(12):979-82. doi: 10.1093/jnci/djr152. Epub 2011 Jun 13.

16.

Breast cancer incidence rates in U.S. women are no longer declining.

DeSantis C, Howlader N, Cronin KA, Jemal A.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):733-9. doi: 10.1158/1055-9965.EPI-11-0061. Epub 2011 Feb 28.

17.

Improved estimates of cancer-specific survival rates from population-based data.

Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA.

J Natl Cancer Inst. 2010 Oct 20;102(20):1584-98. doi: 10.1093/jnci/djq366. Epub 2010 Oct 11.

18.

The impact of underreported Veterans Affairs data on national cancer statistics: analysis using population-based SEER registries.

Howlader N, Ries LA, Stinchcomb DG, Edwards BK.

J Natl Cancer Inst. 2009 Apr 1;101(7):533-6. doi: 10.1093/jnci/djn517. Epub 2009 Mar 24.

19.

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF.

Blood. 2008 Jul 1;112(1):45-52. doi: 10.1182/blood-2008-01-134858. Epub 2008 Apr 28.

20.

The decrease in breast-cancer incidence in 2003 in the United States.

Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA.

N Engl J Med. 2007 Apr 19;356(16):1670-4.

21.

Surveillance endoscopy does not improve survival for patients with local and regional stage colorectal cancer.

Ramsey SD, Howlader N, Etzioni R, Brown ML, Warren JL, Newcomb P.

Cancer. 2007 Jun 1;109(11):2222-8.

22.
23.

Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization.

Kerrigan M, Howlader N, Mandelson MT, Harrison R, Mansley EC, Ramsey SD.

Med Care. 2005 Oct;43(10):1043-8.

PMID:
16166874
24.

Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.

Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM.

J Urol. 2005 Sep;174(3):877-81. Erratum in: J Urol. 2005 Nov;174(5):2071.

PMID:
16093979
25.

Supplemental Content

Loading ...
Support Center